Table 2.
Participants clinical characteristics according to the presence of testosterone deficiency
| Testosterone deficiency (n = 72) |
Without testosterone deficiency (n = 173) |
p value | |
|---|---|---|---|
| Weight [kg, median (IQR)] | 76.3 (25.9) | 71.3 (16.2) | 0.857a |
| Height [cm, median (IQR)] | 171.0 (8.0) | 169.0 (7.5) | 0.204a |
| BMI [(kg/m2), median (IQR)] | 26.5 (16.8) | 25.2 (5.4) | 0.160a |
| Underweight [n (%)] | 5 (7.0) | 6 (3.6) | 0.028b/0.155c |
| Normal weight [n (%)] | 26 (36.3) | 78 (46.2) | |
| Overweight [n (%)] | 23 (32.4) | 67 (39.6) | |
| Obesity [n (%)] | 17 (23.9) | 18 (10.7) | |
| Neck circumference [cm, median (IQR)] | 40.0 (4.8) | 39.0 (3.0) | 0.196a |
| Upper-arm circumference [cm, median (IQR)] | 28.3 (3.8) | 28.0 (3.8) | 0.197a |
| Abdominal circumference [cm, median (IQR)] | 98.0 (13.8) | 93.0 (8.6) | 0.492a |
| Waist circumference [cm, median (IQR)] | 99.5 (19.8) | 93.0 (13.5) | 0.030a |
| Hip circumference [cm, median (IQR)] | 47.0 (6.0) | 47.5 (6.0) | 0.906a |
| Metabolic syndrome [n (%)] | 33 (45.8) | 69 (39.9) | 0.390b |
| Blood pressure [n (%)] | 30 (41.7) | 69 (40.1 %) | 0.822b |
| Systolic blood pressure [median (IQR)] | 133.5 (40.0) | 130.0 (30.0) | 0.007a |
| Diastolic blood pressure [median (IQR)] | 79.0 (25.0) | 80.0 (15.0) | 0.756a |
| Smoking history [n (%)] | |||
| Current | 21 (30.4) | 72 (42.6) | 0.127b |
| Former | 25 (36.2) | 42 (24.9) | |
| Never | 23 (33.3) | 55 (32.5) | |
| Alcohol consumption [n (%)] | 41 (59.4) | 77 (45.6) | 0.052b |
| Total cholesterol [mg/dL, median (IQR)] | 210.0 (69.0) | 221.0 (70.5) | 0.668a |
| LDL cholesterol [mg/dL, median (IQR)] | 129.0 (37.0) | 129.0 (72.8) | 0.573a |
| HDL cholesterol [mg/dL, median (IQR)] | 43.5 (13.3) | 42.5 (13.3) | 0.125a |
| Triglycerides [mg/dL, median (IQR)] | 215.0 (215.3) | 218.0 (162.0) | 0.631a |
| HbA1c [%, median (IQR)] | 5.5 (1.7) | 5.3 (1.0) | 0.016a |
| Total testosterone [ng/mL, median (IQR)] | 2.6 (2.6) | 5.9 (2.7) | <0.001a |
| Free testosterone [ng/dL, median (IQR)] | 5.2 (1.5) | 9.1 (3.6) | <0.001a |
| SHBG [nmol/L, median (IQR)] | 35.2 (44.6) | 46.6 (29.6) | 0.083a |
| LH [mIU/mL, median (IQR)] | 5.0 (4.9) | 5.2 (3.2) | 0.001a |
| FSH [mIU/mL, median (IQR)] | 6.7 (7.1) | 5.1 (4.1) | <0.001a |
| FRS [median (IQR)] | 13.0 (5.0) | 12.0 (6.0) | 0.004a |
| <10 [n (%)] | 16 (22.2) | 66 (38.2) | 0.008b/0.003c |
| 10–20 [n (%)] | 48 (66.7) | 101 (58.4) | |
| >20 [n (%)] | 8 (11.1) | 6 (3.5) | |
| 10-Year ASCVD risk [%, median (IQR)] | 7.1 (6.5) | 6.8 (8.3) | 0.002a |
| Lifetime ASCVD risk [n (%)] | |||
| <40 % | 4 (10.0) | 11 (8.0) | 0.789b |
| 40–50 % | 22 (55.0) | 84 (60.9) | |
| >50 % | 14 (35.0) | 43 (31.2) | |
| Lipodistrophy [n (%)] | 39 (56.5) | 96 (58.5) | 0.776b |
| Waist circumference (>102 cm) [n(%)] | 23 (31.9) | 30 (17.3) | 0.011b |
| No lipodystrophy [n (%)] | 20 (27.8) | 59 (34.3) | 0.321b |
| Isolated central fat accumulation [n (%)] | 13 (18.1) | 13 (7.5) | 0.015b |
| Isolated lipoatrophy [n (%)] | 29 (40.3) | 83 (48.3) | 0.254b |
| Mixed forms of lipodystrophy [n (%)] | 10 (13.9) | 17 (9.8) | 0.355b |
BMI body mass index, LDL low density lipoprotein, HDL high density lipoprotein, HbA1c glycosylated hemoglobin, SHBG sex hormone binding globulin, LH luteinizing hormone, FSH follicle stimulating hormone, FRS Framingham risk score, ASCVD atherosclerotic cardiovascular disease
aMann-Whitney U test; bChi-square test; cLinear by linear association test